Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.

被引：8

作者：

Adjei, Alex A.

Bekaii-Saab, Tanios S.

Berlin, Jordan

Philip, Agop Philip

Mercade, Teresa Macarulla

Walter, Annette

Cupit, Lisa

Liu, Rong

Fields, Scott Z.

Holynskyj, Ariadna

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mayo Clin, Phoenix, AZ USA

[3] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA

[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[5] Vall dHebron Univ Hosp, Barcelona, Spain

[6] Bayer AG, Div Pharmaceut, Berlin, Germany

[7] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

[8] Bayer HealthCare Pharmaceut Inc, Whippany, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS2607

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2607

引用

页数：1